The Federal Trade Commission filed a lawsuit last month against the pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx for their allegedly anticompetitive practices that “artificially inflated” the price of insulin. The legal complaint accuses the PBMs of establishing a “perverse” system of rebates that favors insulin products with higher list prices which in turn contributes to one in four patients being unable to afford insulin products.
top of page
bottom of page
Comments